Immunitybio News - August 4, 2026

🔴 Immunitybio is trading 5.2% down today as wider Q2 net loss offsets strong ANKTIVA revenue growth

Immunitybio is trading 5.2% down now at $6.76 after releasing Q2 earnings that showed a wider GAAP net loss per share, primarily driven by non-cash fair value...

ImmunityBio's second quarter product revenue of $50.7M surges 92%, easily beating estimates, while net loss widens.

ImmunityBio reported second quarter 2026 net product revenue of $50.7 million, a 92% increase year-over-year, marking the eighth consecutive quarter of...